NCT06974617
Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine
Sponsored by Cairo University
This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.
Inclusion Criteria: * Age 18 and 65 years. * Both sexes. * Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta. Exclusion Criteria: * Patients with medication over use headache. * Bleeding disorders. * Abnormal neurological examination. * History of allergy to local anesthetics or BOTOX.
Cairo University
Cairo, Egypt
Identity-resolution confidence concerns registry/entity resolution and does not determine clinical eligibility.
Interested in this trial?
Express your interest and we'll connect you with the trial team.
Your selected profile and contact information may be shared with an authorised trial site, sponsor, or Clintriva coordination team for trial contact and pre-screening. Expressing interest does not mean you are eligible or enrolled.
Conditions